April 8 (Reuters) - OTITOPIC:
* OTITOPIC™ PURSUES ADDITIONAL NEW INDICATION FOR DRY POWDER INHALATION OF ASPIRIN AS A TREATMENT FOR NON-SMALL-CELL LUNG CANCER (NSCLC)
April 8 (Reuters) - OTITOPIC:
* OTITOPIC™ PURSUES ADDITIONAL NEW INDICATION FOR DRY POWDER INHALATION OF ASPIRIN AS A TREATMENT FOR NON-SMALL-CELL LUNG CANCER (NSCLC)